10x Genomics, Inc. (TXG) — SEC Filings
10x Genomics, Inc. (TXG) — 35 SEC filings. Latest: 8-K (Nov 14, 2025). Includes 14 8-K, 6 10-Q, 6 SC 13G/A.
View 10x Genomics, Inc. on SEC EDGAR
Overview
10x Genomics, Inc. (TXG) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 14, 2025: 10x Genomics, Inc. filed an 8-K on November 14, 2025, reporting events as of November 12, 2025. The filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. Specific details regar
Sentiment Summary
Across 35 filings, the sentiment breakdown is: 33 neutral, 2 mixed. The dominant filing sentiment for 10x Genomics, Inc. is neutral.
Filing Type Overview
10x Genomics, Inc. (TXG) has filed 14 8-K, 6 10-Q, 2 DEFA14A, 2 DEF 14A, 2 10-K, 3 SC 13G, 6 SC 13G/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (35)
Risk Profile
Risk Assessment: Of TXG's 23 recent filings, 0 were flagged as high-risk, 10 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $149,002,000 |
| Net Income | $-27,472,000 |
| EPS | N/A |
| Debt-to-Equity | 0.31 |
| Cash Position | $432,508,000 |
| Operating Margin | -21.6% |
| Total Assets | $1,027,361,000 |
| Total Debt | $79,652,000 |
Key Executives
- Chief Executive Officer
- Dr. David R. Walt
- Serge Weisberg
- Dr. Sarah E. Michaels
- Mr. David M. R. Bentley
- Dr. Serge Saxonov
- Mr. Justin McCarville
- Eric S. Whitaker
- Abigail P. Johnson
Industry Context
10x Genomics operates in the rapidly evolving life sciences tools and services market, which is characterized by significant innovation and investment in areas like genomics, proteomics, and spatial biology. The industry is competitive, with companies focusing on developing advanced platforms that enable deeper biological insights. Key trends include the increasing demand for single-cell analysis and multi-omic solutions, driven by advancements in research and diagnostics.
Top Tags
financial-reporting (5) · corporate-governance (4) · 10-Q (4) · annual-meeting (3) · 8-K (3) · financials (3) · proxy-statement (3) · executive-compensation (3) · 10x Genomics (3) · TXG (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net loss (Q3 2025) | $27.472M | Improved from $35.753M in Q3 2024 |
| Net loss (YTD Sep 2025) | $27.292M | Significantly narrowed from $133.599M in YTD Sep 2024 |
| Total revenue (Q3 2025) | $149.002M | Slight decrease from $151.654M in Q3 2024 |
| Gain on settlement | $49.900M | Contributed to reduced net loss for YTD Sep 2025 |
| Cash and cash equivalents (Sep 30, 2025) | $432.508M | Increased from $344.067M at Dec 31, 2024 |
| Net cash provided by operating activities (YTD Sep 2025) | $95.273M | Increased from $13.412M in YTD Sep 2024 |
| Research and development expenses (Q3 2025) | $57.194M | Decreased from $66.174M in Q3 2024 |
| Selling, general and administrative expenses (Q3 2025) | $75.355M | Decreased from $81.704M in Q3 2024 |
| Products and services revenue (Q3 2025) | $148.019M | Decreased from $151.559M in Q3 2024 |
| License and royalty revenue (Q3 2025) | $983K | Increased from $95K in Q3 2024 |
| Q2 2025 Total Revenue | $150.0M | Increased from $130.0M in Q2 2024, showing 15.4% growth. |
| Q2 2025 Product and Service Revenue | $145.0M | Up from $125.0M in Q2 2024, representing 16% year-over-year growth. |
| YTD 2025 Total Revenue | $290.0M | Increased from $250.0M for the same period in 2024, indicating strong half-year performance. |
| Retained Earnings (June 30, 2025) | -$1.2B | An improvement from -$1.3B at December 31, 2024, but still reflects an accumulated deficit. |
| Product and Service Revenue Growth | 16% | Year-over-year growth for Q2 2025, demonstrating strong demand for core offerings. |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a significant, albeit potentially slightly adjusted, stake in 10x Genomics over the next year.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
- {"claim":"The substantial Class B ownership by FMR LLC will continue to give them considerable influence over 10x Genomics' strategic decisions.","entity":"10x Genomics, Inc.","targetDate":"2025-02-09","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for 10x Genomics, Inc. (TXG)?
10x Genomics, Inc. has 35 recent SEC filings from Jan 2024 to Nov 2025, including 14 8-K, 6 10-Q, 6 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TXG filings?
Across 35 filings, the sentiment breakdown is: 33 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find 10x Genomics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all 10x Genomics, Inc. (TXG) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for 10x Genomics, Inc.?
Key financial highlights from 10x Genomics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for TXG?
The investment thesis for TXG includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at 10x Genomics, Inc.?
Key executives identified across 10x Genomics, Inc.'s filings include Chief Executive Officer, Dr. David R. Walt, Serge Weisberg, Dr. Sarah E. Michaels, Mr. David M. R. Bentley and 4 others.
What are the main risk factors for 10x Genomics, Inc. stock?
Of TXG's 23 assessed filings, 0 were flagged high-risk, 10 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from 10x Genomics, Inc.?
Recent forward-looking statements from 10x Genomics, Inc. include guidance on {"claim":"FMR LLC will maintain a significant, albeit potentially slightly adjusted, stake in 10x Genomics over the next and 1 other predictions.